Ticker	Volume	Price	Price Delta
DJIA	12,580.70	+125.86	1.01%
S&P 500	1,332.42	+14.60	1.11%
Nasdaq	2,870.99	+33.46	1.18%

Ticker	Volume	Price	Price Delta
STOXX 50	2,160.31	+12.39	0.58%
FTSE 100	5,391.14	+34.80	0.65%
DAX	6,396.84	+73.65	1.16%

Ticker	Volume	Price	Price Delta
Nikkei	8,612.87	-44.21	-0.51%
TOPIX	722.59	-4.44	-0.61%
Hang Seng	18,726.20	-329.31	-1.73%

Gold

1,550.90

-0.01%

EUR-USD

1.2467

-0.2881%

Nasdaq

2,870.99

+1.18%

DJIA

12,580.70

+1.01%

S&P 500

1,332.42

+1.11%

FTSE 100

5,391.14

+0.65%

STOXX 50

2,160.31

+0.58%

DAX

6,396.84

+1.16%

Oil (WTI)

90.31

-0.50%

U.S. 10-year

1.716%

-0.029

BAC:US

7.44

+4.06%

FB:US

28.84

-9.62%

Bloomberg

Exchange: -
Sector: Consumer, Non-cyclical
Industry: Pharmaceuticals
Sub-Industry: Drug Delivery Systems

Matrixx Initiatives Inc

MTXX:US

Acquired

Matrixx Initiatives Inc (MTXX:US) was acquired by 61128Z:US

Company Profile

Matrixx Initiatives, Inc. is a nutrient and drug delivery technology company that develops, manufactures, and markets delivery systems for bioactive compounds. The Company's subsidiary produces, markets, and sells Zicam Cold Remedy nasal gel and Zicam Allergy Relief nasal gel.